Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Clinical · Molecular biology

RAD51C breast cancer-identified variants with attenuated homologous recombination function exhibit sensitivity to combined PARP1 and ATR inhibition

Summary

This study characterized 33 RAD51C variants identified in breast cancer patients, assessing their ability to perform homologous recombination (HR). Researchers found one HR-deficient variant and five with intermediate HR proficiency. Although these variants exhibited only modestly attenuated HR function, they misregulate replication fork progression and accumulate single-strand DNA gaps. Cells expressing these variants, largely resistant to monotherapy, showed increased sensitivity to a combination of PARP1 inhibitors (Saruparib) and ATR inhibitors (Ceralasertib). These findings suggest that RAD51C variants with partial HR function can lead to profound defects in replicative damage repair, potentially resulting in distinct therapeutic responses.

Critical appraisal

Clinical. This research identifies RAD51C variants with attenuated homologous recombination (HR) function that could serve as predictive biomarkers for combination therapy. The finding that these variants, resistant to PARP1i or ATRi monotherapies, are sensitive to the Saruparib and Ceralasertib combination, suggests a novel therapeutic strategy for a subset of breast cancer patients. This would justify phase II clinical trials to evaluate the efficacy of this combination in patients carrying these specific RAD51C variants. Clinical impact could be seen in the medium term (3-5 years) if these results are validated.

Molecular biology. The study functionally characterized 33 clinical RAD51C variants, identifying those with partial or complete HR deficiency. It highlighted that even partially attenuated HR function can lead to significant defects in replication fork progression and single-strand DNA gap accumulation. The technology used involved in vitro functional assays to assess HR capacity and inhibitor response. The discovery of a new functional C-terminal region of RAD51C is a fundamental advance. These findings have direct translational impact by proposing a molecular mechanism for sensitivity to combination therapy and suggesting that functional profiling of RAD51C variants could guide therapeutic decisions.

The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology